Iain Davis shows how Thiel’s and Musk’s ideologies are becoming policy: Freedom Cities modeled on Próspera, a Ukrainian “digital state,” and privately issued stablecoins - all of which are building toward a multipolar world of gov-corp Technates.
Whitney joined The Jimmy Dore Show to discuss two recent articles, Debt From Above: The Carbon Credit Coup and Manufacturing Consent: The Border Fiasco and the "Smart Wall."
In the first part of their SDG series, Iain Davis and Whitney Webb cut through the UN’s language to show that “sustainable development” uses debt, public-private partnerships and a “reimagined” World Bank and IMF to entrap nations for the benefit of financial elites.
The WEF was not Klaus Schwab’s creation alone. Johnny Vedmore shows how three CFR-linked Harvard figures, Henry Kissinger, John Kenneth Galbraith and nuclear strategist Herman Kahn, recruited Schwab through a CIA-funded seminar and helped launch the Forum.
The “rules-based order” is said to be shifting from West to East, but Iain Davis argues both sides serve the same global public-private partnership. China, built into the world’s first Technate with Western help, is a model for the order now coming for us all.
The AFT and NEA say they back Biden’s school vaccine mandates on health grounds. However, both unions have spent decades partnering with IBM, Microsoft, Google and Gates and these mandates open the door to blockchain vaccine passports and digital IDs for students.
El COVID-19 eliminó las barreras regulatorias relacionadas con los ensayos clínicos que Moderna nunca pudo superar. ¿Cómo se enteró Moderna meses antes que todos que el COVID-19 crearía esas condiciones?
Antes de la COVID-19, Moderna parecía como otra Theranos: secretismo, fuga de directivos, ningún producto en nueve años, una disputa de patentes y una toxicidad que la obligó a abandonar los fármacos de dosis múltiples. La Parte 1 muestra lo cerca que estuvo del colapso, y por qué importa hoy.
Before COVID-19, Moderna looked like another Theranos: secretive, losing top staff, no product after nine years, a patent fight over its delivery system and toxicity so severe it dropped all multi-dose drugs. Part 1 shows how close it was to collapse, and why that matters for boosters.
